Actithera Secures $75.5 Million in Oversubscribed Series A Round
Deal News | Jul 09, 2025 | 4BIO Ventures Management Ltd
In a groundbreaking move, 4BIO Capital has co-led a $75.5 million Series A financing round for Actithera, a company specializing in the development of advanced radiopharmaceutical therapies targeting fibroblast activation protein (FAP). The round was joined by founding investor M Ventures, Hadean Ventures, and Sofinnova Partners, among others. The funds will facilitate the advancement of Actithera's lead FAP asset into clinical development across various indications, while also furthering its robust RLT discovery platform and preclinical pipeline. With a rapidly growing radioligand therapy market, Actithera is poised to make significant strides in improving cancer treatment outcomes with its innovative strategies. The new capital injection underscores a strong validation of Actithera's approach to radio-conjugate engineering, which incorporates rational drug design and covalent-targeting chemistries to optimize tumor retention and minimize toxicity. Dr. Andreas Goutopoulos, founder and CEO of Actithera, emphasizes the company’s commitment to transforming radiopharmaceutical development and bringing to market therapies with enhanced efficacy and patient convenience.
Sectors
- Venture Capital & Private Equity
- Biotechnology & Pharmaceuticals
Geography
- United Kingdom – 4BIO Capital is based in London, which serves as a significant hub for this venture capital activity.
Industry
- Venture Capital & Private Equity – The article involves a significant investment of $75.5 million co-led by 4BIO Capital, a venture capital firm, highlighting the industry's role in funding and nurturing innovative biotech companies.
- Biotechnology & Pharmaceuticals – Actithera operates within the biotechnology sector, focusing on the development of radiopharmaceuticals, a cutting-edge approach in cancer treatment.
Financials
- $75.5 million – The total capital raised in the Series A funding round for Actithera.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| 4BIO Capital | Co-lead investor | Company | A venture capital firm investing in advanced therapies and emerging technologies across high-growth markets. |
| Actithera | Target company | Company | Develops radiopharmaceutical therapies with a focus on FAP-targeting candidates and pipeline expansion. |
| M Ventures | Founding investor and co-lead | Company | An investment arm specializing in science-focused funding, contributing to transformative innovations. |
| Hadean Ventures | Co-lead investor | Company | A life sciences venture capital advisor investing in life science companies across Europe. |
| Sofinnova Partners | Co-lead investor | Company | A leading European venture capital firm in life sciences. |
| Bioqube Ventures | Syndicate participant | Company | Invests in early to mid-stage life sciences companies. |
| Surveyor Capital | Syndicate participant | Company | A unit of Citadel, investing strategically in the healthcare sector. |
| Dr. Andreas Goutopoulos | Founder and CEO | Person | Founder of Actithera, innovative in integrating drug design with radiopharmaceuticals. |
| Therese Liechtenstein | Incoming Board Member and Investment Director | Person | Investment Director at 4BIO Capital, joining Actithera's Board. |